Real-world use of encorafenib plus cetuximab after prior systemic therapy in patients with BRAFV600E-mutant metastatic colorectal cancer: a pooled analysis of European observational studies
Clinical Colorectal Cancer · 2026-11
DOI: 10.1016/j.clcc.2026.11.001 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Colorectal Cancer, 2026-11. Verfasst von Chiara Cremolini und 14 weiteren Autor:innen. Die Arbeit nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Pierre Fabre Médicament SAS.
Abstract (Originalsprache)
Introduction
Encorafenib/cetuximab is the standard-of-care for BRAFV600E-mutant metastatic colorectal cancer (mCRC) after prior systemic therapy. European observational studies have evaluated encorafenib/cetuximab treatment patterns and outcomes; pooling these data allows robust real-world insights.
Methods
This international, multicenter, retrospective, longitudinal, pooled analysis included five European observational studies conducted between 2019 and 2024: four retrospective (B-REAL, CATAMARAN, CONFIDENCE, GONO cohort) and one ongoing prospective (BERING CRC). Data from adults initiating encorafenib/cetuximab for BRAFV600E-mutant mCRC after prior systemic therapy were analyzed. The primary objective was to describe patient demographics and disease characteristics; secondary objectives included treatment patterns/sequence, tumor responses, survival outcomes, and adverse events (AEs).
Results
The pooled analysis included 709 patients. At encorafenib/cetuximab initiation, median age was 65 years; 70.9% had synchronous metastases and 30.9% had ≥3 metastatic sites. Encorafenib/cetuximab was administered as second-, third-, and fourth- or later-line in 66.1%, 21.3%, and 7.9% of patients, respectively, and in 4.7% following relapse within 6 months of adjuvant therapy (after prior systemic treatment [APST]). Among 493 evaluable patients, the objective response rate was 28.0%. Median progression-free survival (PFS) was 5.0 months (95% confidence interval [CI] 4.7–5.3), and median overall survival (OS) was 9.0 months (95% CI 8.0–9.9). PFS and OS were longer in APST patients than in those treated in second- or later-line settings, and in long responders (progression ≥9 months after treatment initiation) compared with fragile patients (aged >70 years with Eastern Cooperative Oncology Group performance status >0) and those aged ≤50 years. In the safety population (n=547), 85.2% of patients experienced on-treatment AEs, most commonly fatigue, decreased appetite, asthenia, nausea, and anemia.
Conclusions
Across Europe, encorafenib/cetuximab use in clinical practice in patients with BRAFV600E-mutant mCRC had effectiveness and safety outcomes consistent with clinical trials and previous real-world studies, providing further real-world evidence supporting its use in routine clinical care.
Förderung
- Pierre Fabre Médicament SAS
Zitieren
APA
Cremolini, C., Taieb, J., Martinelli, E., Montes, A. F., Elez, E., Roodhart, J. M., Alig, A., Germani, M. M., Gallois, C., Domarco, P. S., Koopman, M., Attar, H., Ruhier, K., Carrère, F., & Stintzing, S. (2026). Real-world use of encorafenib plus cetuximab after prior systemic therapy in patients with BRAFV600E-mutant metastatic colorectal cancer: a pooled analysis of European observational studies. Clinical Colorectal Cancer. https://doi.org/10.1016/j.clcc.2026.11.001
Vancouver
Cremolini C, Taieb J, Martinelli E, Montes AF, Elez E, Roodhart JM, et al. Real-world use of encorafenib plus cetuximab after prior systemic therapy in patients with BRAFV600E-mutant metastatic colorectal cancer: a pooled analysis of European observational studies. Clinical Colorectal Cancer. 2026. doi:10.1016/j.clcc.2026.11.001
BibTeX
@article{Cremolini2026,
author = {Cremolini, Chiara and Taieb, Julien and Martinelli, Erika and Montes, Ana Fernandez and Elez, Elena and Roodhart, Jeanine M.L. and Alig, Annabel and Germani, Marco Maria and Gallois, Claire and Domarco, Paula Sampedro and Koopman, Miriam and Attar, Hanane and Ruhier, Kalaivani and Carrère, Florence and Stintzing, Sebastian},
title = {Real-world use of encorafenib plus cetuximab after prior systemic therapy in patients with BRAFV600E-mutant metastatic colorectal cancer: a pooled analysis of European observational studies},
journal = {Clinical Colorectal Cancer},
year = {2026},
doi = {10.1016/j.clcc.2026.11.001}
}
EUVIMED